Epigenetics Market Poised for Robust 18% CAGR Growth Driven by R&D and Therapeutics Demand
The epigenetics market is expected to grow significantly in the coming years, reaching $4.3 billion by 2028 at a CAGR of 18.3% from 2023-2028. The growth is driven by increased investment in epigenetics research and the rising demand for epigenetic-based therapeutics. However, limited applications in toxicology and quality concerns over antibodies may restrain market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
The
kits and reagents segment, which includes antibodies, ChiP-seq kits,
bisulfite conversion kits, and more, is expected to hold the dominant
position in the epigenetics market during the forecast period. This is
due to the development of advanced, easy-to-use, and affordable
epigenetics kits and reagents.
North America accounted for the
largest share of the epigenetics market in 2022 due to the presence of
epigenetic manufacturing companies in the region and favorable
government and private initiatives supporting the adoption of
next-generation sequencing technologies.
Key players operating
in the epigenetics market include Thermo Fisher Scientific, Illumina,
PacBio, Abcam, Merck KGaA, Active Motif, Bio-Rad Laboratories, Promega
Corporation, Zymo Research Corporation, F. Hoffmann-La Roche Ltd, and
others. Recent developments in the market include PacBio's acquisition
of Apton Biosystems to accelerate next-generation sequencing technology
and Illumina's agreement with SomaLogic to introduce proteomic assays on
Illumina's NGS platforms.
The epigenetics market is segmented by
product and service, method, technique, application, end user, and
region. Product and service segments include kits and reagents, enzymes,
instruments and accessories, software, and services. Methods include
DNA methylation, histone modifications, and other methods like
non-coding RNA. Key techniques are next-generation sequencing, PCR/qPCR,
mass spectrometry, and sonication. Major applications are in oncology,
metabolic diseases, immunology, developmental biology, and more. End
users comprise academic and research institutes, biotech and
pharmaceutical companies, and hospitals and clinics.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=896
The
integration of AI and machine learning in epigenetics presents
significant opportunities to transform the understanding of epigenetic
mechanisms. However, concerns around antibody quality and limited
applications in toxicology remain challenges inhibiting market growth.
Overall, increasing R&D investment, demand for epigenetic
therapeutics, advancements in biotechnology, and growth in application
areas are expected to drive steady expansion of the global epigenetics
market through 2028.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment